ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.480,89
0,21%
S&P 500
5.187,67
0,00%
US Dollar vs BRL
5,0913
0,04%
Bitcoin
61.172,63
-0,02%
Brent Oil
83,885
0,39%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Sanofi (SNY)

  7. Sanofi (SNY) Notícias

SNY

Sanofi (SNY)

Sanofi
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SNY
DataHoraFonteTítuloCódigoCompanhia
25/04/202408:52IH Market NewsSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on EarningsNASDAQ:SNYSanofi
19/04/202408:31IH Market NewsParamount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and MoreNASDAQ:SNYSanofi
23/02/202416:02Edgar (US Regulatory)Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).NASDAQ:SNYSanofi
23/02/202413:15Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:SNYSanofi
15/02/202414:09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SNYSanofi
14/02/202417:57Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SNYSanofi
25/01/202416:29GlobeNewswire Inc.Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)NASDAQ:SNYSanofi
23/01/202408:05Dow Jones NewsSanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- UpdateNASDAQ:SNYSanofi
23/01/202407:40IH Market NewsWall Street Highlights: Vroom Shuts Down Online Car Sales, Ericsson Warns of Decline Outside China, and MoreNASDAQ:SNYSanofi
23/01/202403:00PR Newswire (US)Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2BNASDAQ:SNYSanofi
09/01/202404:14Dow Jones NewsSanofi Names Brian Foard Head of Specialty-Care UnitNASDAQ:SNYSanofi
21/12/202304:25Dow Jones NewsSanofi Ends Drug Program After Late-Stage Trial in Lung Cancer FailsNASDAQ:SNYSanofi
19/12/202309:28Dow Jones NewsInnate Pharma Shares Rise after Sanofi Exercises Licensing OptionNASDAQ:SNYSanofi
12/12/202307:50IH Market NewsHasbro Job Cuts, Oracle’s Stock Decline, Google’s Epic Antitrust Loss, and MoreNASDAQ:SNYSanofi
11/12/202319:18Dow Jones NewsSanofi Terminates Agreement with Maze Therapeutics Following FTC OppositionNASDAQ:SNYSanofi
11/12/202303:50Dow Jones NewsSanofi Sees Improvement in Trial Results of Cancer Drug SarclisaNASDAQ:SNYSanofi
07/12/202304:34Dow Jones NewsSanofi Myeloma Drug Sarclisa Met Primary Goal in Late-Stage TrialNASDAQ:SNYSanofi
07/12/202304:20Dow Jones NewsSanofi Sees Annual Sales From New Pharma Assets Above $10.8 Billion by 2030NASDAQ:SNYSanofi
06/12/202310:20Dow Jones NewsTrending: Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage TrialsNASDAQ:SNYSanofi
06/12/202307:14Dow Jones NewsMerck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage TrialsNASDAQ:SNYSanofi
30/11/202311:23Dow Jones NewsTeva Closes Collaboration Deal With Sanofi on IBD TreatmentNASDAQ:SNYSanofi
30/11/202310:30Business WireTeva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease TreatmentNASDAQ:SNYSanofi
27/11/202312:31Dow Jones NewsTrending: Sanofi's Notus Trial Meets Primary EndpointNASDAQ:SNYSanofi
27/11/202304:40Dow Jones NewsSanofi Says Notus Phase 3 Trial of Dupixent Met Primary EndpointNASDAQ:SNYSanofi
27/11/202303:30GlobeNewswire Inc.Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious DiseaseNASDAQ:SNYSanofi
07/11/202318:01AllPennyStocks.comOrphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That TimeNASDAQ:SNYSanofi
07/11/202310:56Dow Jones NewsSanofi Under Preliminary Probe in France Over Possible Market Manipulation, Source SaysNASDAQ:SNYSanofi
07/11/202309:10IH Market NewsTuesday’s Wall Street Highlights: WeWork, UBS, Sanofi, Alteryx, Intel, and more.NASDAQ:SNYSanofi
06/11/202309:50Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SNYSanofi
02/11/202313:15PR Newswire (US)Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communitiesNASDAQ:SNYSanofi
 Apresentando as notícias mais relevantes sobre:NASDAQ:SNY

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
BOV
OIBR3
OI ON
BOV
VVEO3
CM Hospitalar ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
JHSF3
JHSF PART ON
BOV
BRKM5
BRASKEM PNA
BOV
PRIO3
PETRORIO ON
BOV
HBRE3
HBR Realty Empreendiment... ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
SGPS3
SPRINGS ON
BOV
ENAT3
ENAUTA ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados